title: Efficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a randomized controlled trial.
abstract: BACKGROUND
  Epicardial adipose tissue (EAT) is a newly discovered independent risk factor for coronary atherosclerosis. There is a scarcity of information on the reduction of EAT volume to reduce atherosclerosis risk. Coronary computed tomography angiography (CCTA) has emerged as a noninvasive imaging method for the analysis of coronary atherosclerosis and EAT volume. The purpose of this trial is to determine whether olmesartan medoxomil is effective at both treatment of coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA.
  
  
  METHODS
  This study is a prospective, single-center, open-label, randomized controlled clinical trial aimed at exploring the efficacy of olmesartan medoxomil on coronary atherosclerosis and EAT. A total of 194 patients with coronary stenosis greater than 30 % and less than 70 % detected by CCTA will be randomly divided into olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). The primary outcome measures include coronary atherosclerosis progression and EAT volume reduction, as detected by CCTA at 12 months. The secondary outcome measures include the levels of blood lipids, glucose, high-sensitivity C-reactive protein, IL-6, monocyte chemotactic protein 1, TNF-α, matrix metalloproteinase 9, NO, endothelin 1, adiponectin, and leptin at baseline and after 6 and 12 months.
  
  
  CONCLUSIONS
  Treatments aimed at reducing EAT volume can eventually achieve an antiatherosclerotic effect. This is the first trial designed to explore the effect of olmesartan medoxomil on both coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA.
  
  
  BACKGROUND
  ClinicalTrials.gov: NCT02360956 .
authors.affiliation: Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. zhouying0129@126.com.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. tianfeng301@126.com.
authors.forename: Feng
authors.initials: F
authors.lastname: Tian
authors.affiliation: Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. wangjing121@126.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. fearlessly@126.com.
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Yang
authors.affiliation: Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. zhangtao301@163.com.
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. jjing301@126.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Jing
authors.affiliation: Department of Cardiology, Chinese PLA General Hospital, Beijing, 100853, China. cyundai301@126.com.
authors.forename: Yun-Dai
authors.initials: YD
authors.lastname: Chen
mesh_terms: D000273:Adipose Tissue / Q000473:pathology*; D002985:Clinical Protocols; D017023:Coronary Angiography / Q000379:methods*; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D000068557:Olmesartan Medoxomil / Q000627:therapeutic use*; D010496:Pericardium / Q000473:pathology*; D011446:Prospective Studies; D018401:Sample Size; D014057:Tomography, X-Ray Computed
chemical_list: D000068557:Olmesartan Medoxomil